Steve Lundy becomes AspenBio CEO
This article was originally published in Clinica
Diagnostics firm AspenBio Pharma has appointed Steve Lundy to the position of CEO. Mr Lundy, who will also join the company’s board of directors, recently served as CEO of bacterial diagnostics specialist MicroPhage. He has also held senior executive roles at Vermillion and GeneOhm (which was acquired by BD in 2006). Mr Lundy will replace Daryl Faulkner, who held the role of interim CEO since 2009. Mr Faulkner will continue as executive chairman. AspenBio (Castle Rock, Colorado) is currently developing the AppyScore, a blood-based test for evaluating patients suspected of having acute appendicitis.